JP2023541457A5 - - Google Patents
Info
- Publication number
- JP2023541457A5 JP2023541457A5 JP2023516769A JP2023516769A JP2023541457A5 JP 2023541457 A5 JP2023541457 A5 JP 2023541457A5 JP 2023516769 A JP2023516769 A JP 2023516769A JP 2023516769 A JP2023516769 A JP 2023516769A JP 2023541457 A5 JP2023541457 A5 JP 2023541457A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- grna
- nuclease
- cell population
- genetically modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078035P | 2020-09-14 | 2020-09-14 | |
| US63/078,035 | 2020-09-14 | ||
| PCT/US2021/050328 WO2022056489A1 (en) | 2020-09-14 | 2021-09-14 | Compositions and methods for cd38 modification |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023541457A JP2023541457A (ja) | 2023-10-02 |
| JP2023541457A5 true JP2023541457A5 (https=) | 2024-09-26 |
Family
ID=78080565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023516769A Abandoned JP2023541457A (ja) | 2020-09-14 | 2021-09-14 | Ｃｄ３８修飾のための化合物および方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230398219A1 (https=) |
| EP (1) | EP4211244A1 (https=) |
| JP (1) | JP2023541457A (https=) |
| WO (1) | WO2022056489A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3110837A1 (en) | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| BR112023024983A2 (pt) * | 2021-06-02 | 2024-04-30 | Metagenomi Inc | Sistemas crispr classe ii, tipo v |
| JP2024540723A (ja) * | 2021-11-03 | 2024-11-01 | インテリア セラピューティクス，インコーポレーテッド | 免疫療法のためのｃｄ３８組成物及び方法 |
| AU2023251040A1 (en) * | 2022-04-04 | 2024-10-17 | Vor Biopharma Inc. | Compositions and methods for mediating epitope engineering |
| AU2023276763A1 (en) | 2022-05-25 | 2024-12-12 | Metagenomi Therapeutics, Inc. | Supplementation of liver enzyme expression |
| KR20260036568A (ko) * | 2023-07-10 | 2026-03-17 | 카스젠 라이프 사이언스 씨오., 엘티디. | 세포 면역 요법용 조성물, 및 방법 |
| WO2025030010A1 (en) | 2023-08-01 | 2025-02-06 | Vor Biopharma Inc. | Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| SMT202000031T1 (it) | 2010-06-09 | 2020-03-13 | Genmab As | Anticorpi contro cd38 umano |
| AU2013266968B2 (en) | 2012-05-25 | 2017-06-29 | Emmanuelle CHARPENTIER | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| WO2015157070A2 (en) | 2014-04-09 | 2015-10-15 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating cystic fibrosis |
| CA2969619A1 (en) | 2014-12-03 | 2016-06-09 | Agilent Technologies, Inc. | Guide rna with chemical modifications |
| CN107406506A (zh) | 2014-12-04 | 2017-11-28 | 詹森生物科技公司 | 用于治疗急性髓系白血病的抗cd38抗体 |
| KR102888521B1 (ko) | 2015-04-06 | 2025-11-19 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna |
| WO2017025323A1 (en) * | 2015-08-11 | 2017-02-16 | Cellectis | Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation |
| AU2016337525B2 (en) | 2015-10-16 | 2022-01-20 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for inhibition of lineage specific antigens |
| IL310721B2 (en) | 2015-10-23 | 2025-11-01 | Harvard College | Nucleobase editors and uses thereof |
| US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
| CA3048434A1 (en) | 2016-12-30 | 2018-07-05 | Editas Medicine, Inc. | Synthetic guide molecules, compositions and methods relating thereto |
| RU2019130504A (ru) | 2017-02-28 | 2021-03-30 | Вор Байофарма, Инк. | Композиции и способы ингибирования линиеспецифических белков |
| US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| KR20240116572A (ko) | 2017-03-23 | 2024-07-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
| US11718659B2 (en) | 2017-08-28 | 2023-08-08 | The Trustees Of Columbia University In The City Of New York | CD33 exon 2 deficient donor stem cells for use with CD33 targeting agents |
| EA202092044A1 (ru) | 2018-03-14 | 2021-03-03 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные рецепторы антигена против cd33 и их применения |
| KR102817092B1 (ko) * | 2018-03-29 | 2025-06-09 | 페이트 세러퓨틱스, 인코포레이티드 | 조작된 면역 효과기 세포 및 이의 용도 |
| CA3110837A1 (en) * | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| EP3987087A4 (en) * | 2019-06-21 | 2023-11-15 | Function Oncology, Inc. | GENETIC PHARMACEOPIA FOR COMPREHENSIVE FUNCTIONAL PROFILING OF HUMAN CANCERS |
-
2021
- 2021-09-14 JP JP2023516769A patent/JP2023541457A/ja not_active Abandoned
- 2021-09-14 WO PCT/US2021/050328 patent/WO2022056489A1/en not_active Ceased
- 2021-09-14 EP EP21787233.2A patent/EP4211244A1/en not_active Withdrawn
- 2021-09-14 US US18/026,080 patent/US20230398219A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023541457A5 (https=) | ||
| AU2021282533C1 (en) | Optimized crispr/cas9 systems and methods for gene editing in stem cells | |
| JP7038079B2 (ja) | Ｃｒｉｓｐｒハイブリッドｄｎａ／ｒｎａポリヌクレオチドおよび使用方法 | |
| JP2023541458A5 (https=) | ||
| KR102699944B1 (ko) | Rna-가이드된 엔도뉴클레아제를 이용하는 게놈 조작에서 특이성을 개선하는 조성물 및 방법 | |
| US20230392131A1 (en) | Reprogrammable iscb nucleases and uses thereof | |
| AU2024259841A1 (en) | CRISPR-Cas-related methods, compositions and components for cancer immunotherapy | |
| KR20180120752A (ko) | 베타 이상헤모글로빈증의 치료를 위한 crispr/cas-관련 방법 및 조성물 | |
| CA2982966C (en) | Evaluation of cas9 molecule/guide rna molecule complexes | |
| AU2016244033A1 (en) | CRISPR/CAS-related methods and compositions for treating Duchenne Muscular Dystrophy and Becker Muscular Dystrophy | |
| JP2022534813A5 (https=) | ||
| JP2024502114A (ja) | Ｖ型ＣａｓシステムのためのガイドＲＮＡデザインおよび複合体 | |
| US20240318165A1 (en) | Type i-b crispr-associated transposase systems | |
| WO2015148860A1 (en) | Crispr/cas-related methods and compositions for treating beta-thalassemia | |
| US20220380758A1 (en) | Type i-b crispr-associated transposase systems | |
| US20250236857A1 (en) | Engineered chimeric iscb polypeptides and uses thereof | |
| JP2024502348A (ja) | Ｔｒａｃｒ不含 Ｖ型Ｃａｓシステム用のガイドＲＮＡデザインおよび複合体 | |
| JP2024502820A5 (https=) | ||
| CA3204429A1 (en) | Dna nuclease guided transposase compositions and methods of use thereof | |
| JP2024529425A5 (https=) | ||
| JP2023547887A5 (https=) | ||
| US20230383272A1 (en) | Nucleic acid-guided nucleases and use thereof | |
| Mishra et al. | CRISPR-Cas9: A potent gene-editing tool for the treatment of cancer | |
| JP2024528202A5 (https=) | ||
| US20250223577A1 (en) | Hybrid crispr-cas systems and methods of use thereof |